{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:39:52Z","timestamp":1793194792437,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp;amp; Translational All"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Garadacimab, a first\u2010in\u2010class, recombinant monoclonal antibody targeting activated FXII, is available in Germany for long\u2010term prophylaxis (LTP) of hereditary angioedema (HAE) since March 2025. We aimed to examine garadacimab real\u2010life treatment outcomes at our Berlin Angioedema Center of Reference and Excellence (ACARE), the reasons for switching therapies, and approaches to tailoring treatment individually.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In total, 29 patients (27 patients with HAE and 2 patients with angioedema due to acquired C1 inhibitor deficiency) were treated in regular care with garadacimab; 3 patients discontinued garadacimab due to lack of efficacy after loading dose or second dose and were excluded from analysis due to insufficient follow up. Ultimately, 26 patients were monitored for 26\u00a0weeks (median) using the angioedema control test (AECT) and the angioedema quality of life questionnaire (AE\u2010QoL). In seven patients, garadacimab from the open\u2010label\u2010VANGUARD study was continued in regular care. Patients who had previously participated in the study\u2014provided they were symptom\u2010free\u2014were offered the option, upon transitioning to routine care, to extend the interval between injections by alternating between three and four days. Patients who were switched to garadacimab in routine care were offered the same option if they were completely symptom\u2010free 2\u00a0months after starting the therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 16 patients switched from previous LTP to garadacimab mostly at the end of their individual treatment interval and due to the prospect of higher efficacy and convenience. The injection interval could be extended in most patients (median, 42\u00a0days, range 31\u201356). The mean AECT and AE\u2010QoL improved clinically meaningfully, regardless of previous treatment (9.2\u201314.4 and 35.5\u201314.9 points, respectively), however, improvement in patients switched from previous LTP was less pronounced when compared to patients that switched from on\u2010demand treatment (11.2\u201314.5 vs. 6.7\u201314.2 points and 29.4\u201314.3 vs. 43.1\u201315.7 points, respectively). No side effects were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Garadacimab showed high efficacy and safety and the gradual extension of injection intervals presented underline its potential for longer dosing intervals that may further reduce treatment burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/clt2.70205","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:39:51Z","timestamp":1791772791000},"source":"Crossref","is-referenced-by-count":0,"title":["Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema"],"prefix":"10.1002","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9218-5468","authenticated-orcid":false,"given":"Markus","family":"Magerl","sequence":"first","affiliation":[{"name":"Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology Charit\u00e9 \u2013 University Medical Center Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6055-6787","authenticated-orcid":false,"given":"Kathrin","family":"Sch\u00f6n","sequence":"additional","affiliation":[{"name":"Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology Charit\u00e9 \u2013 University Medical Center Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6660-167X","authenticated-orcid":false,"given":"Janine","family":"Ruhe","sequence":"additional","affiliation":[{"name":"Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology Charit\u00e9 \u2013 University Medical Center Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2105-6060","authenticated-orcid":false,"given":"Felix","family":"Aulenbacher","sequence":"additional","affiliation":[{"name":"Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology Charit\u00e9 \u2013 University Medical Center Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-0372","authenticated-orcid":false,"given":"Leonie Shirin","family":"Herzog","sequence":"additional","affiliation":[{"name":"Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology Charit\u00e9 \u2013 University Medical Center Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9389-1767","authenticated-orcid":false,"given":"Thomas","family":"Buttgereit","sequence":"additional","affiliation":[{"name":"Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology Charit\u00e9 \u2013 University Medical Center Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,11]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100627"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.04.001"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2023.1263432"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.12.032"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016\u2010025\u201009027\u20104"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.03.024"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010025\u201003562\u20101"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.5414\/alx02603e"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.016"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2314192"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2402478"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.16773"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.015"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)00350\u20101"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.04.072"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1405317"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14293"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/jaa.s284029"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15214"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70009"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016\u2010024\u201009006\u20101"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/skinhd\/vzaf055"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.11.039"}],"container-title":["Clinical and Translational Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.70205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/clt2.70205","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.70205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:29:32Z","timestamp":1793194172000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clt2.70205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/clt2.70205"],"URL":"https:\/\/doi.org\/10.1002\/clt2.70205","archive":["Portico"],"relation":{},"ISSN":["2045-7022","2045-7022"],"issn-type":[{"value":"2045-7022","type":"print"},{"value":"2045-7022","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"article-number":"e70205"}}